Non-coding RNAs in Cancer Diagnosis and Therapy

Overview

Journal Noncoding RNA Res

Date 2018 Aug 31

PMID 30159413

Citations 29

Authors

Mahmood Rasool

Arif Malik

Sara Zahid

Muhammad Abdul Basit Ashraf

Mahmood Husain Qazi

Muhammad Asif

Ahmad Zaheer

Muhammad Arshad

Amir Raza

Mohammad Sarwar Jamal

Affiliations

Soon will be listed here.

Abstract

Cancer invasion involves a series of fundamental heterogeneous steps, with each step being distinct in its type regarding its dependence on various oncogenic pathways. Over the past few years, researchers have been focusing on targeted therapies to treat malignancies relying not only on a single oncogenic pathway, but on multiple pathways. Scientists have recently identified potential targets in the human genome considered earlier as non-functional but the discovery of their potential role in gene regulation has put new insights to cancer diagnosis, prognosis and therapeutics. Non coding RNAs (ncRNAs) have been identified as the key gene expression regulators. Long non-coding RNA (lncRNAs) reveal diverse gene expression profiles in benign and metastatic tumours. Improved clinical research may lead to better knowledge of their biogenesis and mechanism and eventually be used as diagnostic biomarkers and therapeutic agents. Small non coding RNAs or micro RNA (miRNA) are capable of reprogramming multiple oncogenic cascades and, thus, can be used as target agents. This review is aimed to give a perspective of non coding transcription in cancer metastasis with an eye on rising clinical relevance of non coding RNAs and their mechanism of action focusing on potential therapeutics for cancer pathogenesis.

Citing Articles

Corruptive Reprograming of Macrophages into Tumor-Associated Macrophages: The Transcriptional, Epigenetic and Metabolic Basis.

Ahmad A Cancers (Basel). 2023; 15(17).

PMID: 37686567 PMC: 10487138. DOI: 10.3390/cancers15174291.

Telomerase RNA component lncRNA as potential diagnostic biomarker promotes CRC cellular migration and apoptosis evasion via modulation of β-catenin protein level.

Bakr M, Abd-Elmawla M, Elimam H, Gamal El-Din H, Fawzy A, Abulsoud A Noncoding RNA Res. 2023; 8(3):302-314.

PMID: 37032720 PMC: 10074408. DOI: 10.1016/j.ncrna.2023.03.004.

Meta-analysis of transcriptomics data identifies potential biomarkers and their associated regulatory networks in gallbladder cancer.

Singh N, Sharma R, Bose S Gastroenterol Hepatol Bed Bench. 2023; 15(4):311-325.

PMID: 36762219 PMC: 9876761. DOI: 10.22037/ghfbb.v15i4.2292.

Prognostic and diagnostic values of non-coding RNAs as biomarkers for breast cancer: An umbrella review and pan-cancer analysis.

Bahramy A, Zafari N, Rajabi F, Aghakhani A, Jayedi A, Khaboushan A Front Mol Biosci. 2023; 10:1096524.

PMID: 36726376 PMC: 9885171. DOI: 10.3389/fmolb.2023.1096524.

Epigenetic Features in Uterine Leiomyosarcoma and Endometrial Stromal Sarcomas: An Overview of the Literature.

De Almeida B, Dos Anjos L, Dobroff A, Baracat E, Yang Q, Al-Hendy A Biomedicines. 2022; 10(10).

PMID: 36289829 PMC: 9599831. DOI: 10.3390/biomedicines10102567.

References

Wahlestedt C . Targeting long non-coding RNA to therapeutically upregulate gene expression. Nat Rev Drug Discov. 2013; 12(6):433-46. DOI: 10.1038/nrd4018. View

Jiang K . Biotech comes to its 'antisenses' after hard-won drug approval. Nat Med. 2013; 19(3):252. DOI: 10.1038/nm0313-252. View

Modarresi F, Faghihi M, Lopez-Toledano M, Pedram Fatemi R, Magistri M, Brothers S . Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation. Nat Biotechnol. 2012; 30(5):453-9. PMC: 4144683. DOI: 10.1038/nbt.2158. View

Hu X, Li W, Liu G, Wu H, Gao Y, Chen S . The effect of Bcl-2 siRNA combined with miR-15a oligonucleotides on the growth of Raji cells. Med Oncol. 2013; 30(1):430. DOI: 10.1007/s12032-012-0430-6. View

. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012; 489(7414):57-74. PMC: 3439153. DOI: 10.1038/nature11247. View

Trang P, Wiggins J, Daige C, Cho C, Omotola M, Brown D . Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther. 2011; 19(6):1116-22. PMC: 3129804. DOI: 10.1038/mt.2011.48. View

Guttman M, Amit I, Garber M, French C, Lin M, Feldser D . Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature. 2009; 458(7235):223-7. PMC: 2754849. DOI: 10.1038/nature07672. View

Bader A, Brown D, Stoudemire J, Lammers P . Developing therapeutic microRNAs for cancer. Gene Ther. 2011; 18(12):1121-6. PMC: 3910432. DOI: 10.1038/gt.2011.79. View

Bockhorn J, Dalton R, Nwachukwu C, Huang S, Prat A, Yee K . MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun. 2013; 4:1393. PMC: 3723106. DOI: 10.1038/ncomms2393. View

10.

Van Rooij E, Olson E . MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov. 2012; 11(11):860-72. PMC: 6813819. DOI: 10.1038/nrd3864. View

11.

Song S, Poliseno L, Song M, Ala U, Webster K, Ng C . MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell. 2013; 154(2):311-324. PMC: 3767157. DOI: 10.1016/j.cell.2013.06.026. View

12.

Flemming A . Regulatory watch: pioneering gene therapy on brink of approval. Nat Rev Drug Discov. 2012; 11(9):664. DOI: 10.1038/nrd3835. View

13.

Poliseno L, Salmena L, Zhang J, Carver B, Haveman W, Pandolfi P . A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature. 2010; 465(7301):1033-8. PMC: 3206313. DOI: 10.1038/nature09144. View

14.

Redis R, Calin S, Yang Y, You M, Calin G . Cell-to-cell miRNA transfer: from body homeostasis to therapy. Pharmacol Ther. 2012; 136(2):169-74. PMC: 3855335. DOI: 10.1016/j.pharmthera.2012.08.003. View

15.

Yang S, Li Y, Gao J, Zhang T, Li S, Luo A . MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1. Oncogene. 2012; 32(36):4294-303. DOI: 10.1038/onc.2012.432. View

16.

Vickers K, Palmisano B, Shoucri B, Shamburek R, Remaley A . MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011; 13(4):423-33. PMC: 3074610. DOI: 10.1038/ncb2210. View

17.

Uhlmann S, Mannsperger H, Zhang J, Horvat E, Schmidt C, Kublbeck M . Global microRNA level regulation of EGFR-driven cell-cycle protein network in breast cancer. Mol Syst Biol. 2012; 8:570. PMC: 3293631. DOI: 10.1038/msb.2011.100. View

18.

Kluiver J, Gibcus J, Hettinga C, Adema A, Richter M, Halsema N . Rapid generation of microRNA sponges for microRNA inhibition. PLoS One. 2012; 7(1):e29275. PMC: 3253070. DOI: 10.1371/journal.pone.0029275. View

19.

Thorsen S, Obad S, Jensen N, Stenvang J, Kauppinen S . The therapeutic potential of microRNAs in cancer. Cancer J. 2012; 18(3):275-84. DOI: 10.1097/PPO.0b013e318258b5d6. View

20.

Pencheva N, Tavazoie S . Control of metastatic progression by microRNA regulatory networks. Nat Cell Biol. 2013; 15(6):546-54. PMC: 4678324. DOI: 10.1038/ncb2769. View